We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
It is particularly difficult to treat some groups of childhood cancer patients, especially infants in their first weeks of life. This application is to fund this rapidly developing research programme for two years, involving the treatment of 150-200.
Evaluating a novel protein methyltransferase inhibitor for poor-prognosis rhabdomyosarcoma therapy
Diffuse midline glioma is a devastating brain tumour, affecting primarily young children. There’s currently no cure for this disease and treatment options are limited. This is mainly because this type of tumour is well-protected from drugs by the ‘blood-brain barrier’. This barrier physically blocks all medications from entering the brain. Our group has developed new methods of bypassing this barrier using focused ultrasound.
Looking at whether medicines that prevent circular DNA replication can help prevent relapse.
Studying how neuroblastoma cells and immune cells interact over time to see how the cancer adapts to treatment.
Looking at how cancer cells alter the scaffolding inside the body that organises cells in order to spread and make new tumours.
Testing a new type of targeted treatment that applies to multiple types of childhood cancers.
Creating an immunotherapy that can be delivered to patients more quickly and cost-effectively.
Testing medicines that can correct the genetic messages that help cancer cells grow out of control.
